Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,036 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation.
Gagelmann N, Eikema DJ, Stelljes M, Beelen D, de Wreede L, Mufti G, Knelange NS, Niederwieser D, Friis LS, Ehninger G, Nagler A, Yakoub-Agha I, Meijer E, Ljungman P, Maertens J, Kanz L, Lopez-Corral L, Brecht A, Craddock C, Finke J, Cornelissen JJ, Bernasconi P, Chevallier P, Sierra J, Robin M, Kröger N. Gagelmann N, et al. Among authors: meijer e. Haematologica. 2019 May;104(5):929-936. doi: 10.3324/haematol.2018.200808. Epub 2019 Jan 17. Haematologica. 2019. PMID: 30655377 Free PMC article.
Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation.
van Esser JW, Niesters HG, Thijsen SF, Meijer E, Osterhaus AD, Wolthers KC, Boucher CA, Gratama JW, Budel LM, van der Holt B, van Loon AM, Löwenberg B, Verdonck LF, Cornelissen JJ. van Esser JW, et al. Among authors: meijer e. Br J Haematol. 2001 Jun;113(3):814-21. doi: 10.1046/j.1365-2141.2001.02789.x. Br J Haematol. 2001. PMID: 11380475 Free article.
Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.
van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, van Loon AM, Frassoni F, Bacigalupo A, Schaefer UW, Osterhaus AD, Gratama JW, Löwenberg B, Verdonck LF, Cornelissen JJ. van Esser JW, et al. Among authors: meijer e. Blood. 2001 Aug 15;98(4):972-8. doi: 10.1182/blood.v98.4.972. Blood. 2001. PMID: 11493441 Free article.
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF, Löwenberg B, Cornelissen JJ. van Esser JW, et al. Among authors: meijer e. Blood. 2002 Jun 15;99(12):4364-9. doi: 10.1182/blood.v99.12.4364. Blood. 2002. PMID: 12036863 Free article. Clinical Trial.
Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia.
Lodewyck T, Oudshoorn M, van der Holt B, Petersen E, Spierings E, von dem Borne PA, Schattenberg A, Allebes W, Groenendijk-Sijnke M, Duinhouwer L, Willemze R, Lowenberg B, Verdonck LF, Meijer E, Cornelissen JJ. Lodewyck T, et al. Among authors: meijer e. Leukemia. 2011 Oct;25(10):1548-54. doi: 10.1038/leu.2011.123. Epub 2011 May 24. Leukemia. 2011. PMID: 21606965
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, Cornelissen JJ, Janssen JJ, Huisman C, Cornelisse PB, Bruijnen CP, Emmelot M, Sonneveld P, Lokhorst HM, Mutis T, Minnema MC. Kneppers E, et al. Among authors: meijer e. Blood. 2011 Sep 1;118(9):2413-9. doi: 10.1182/blood-2011-04-348292. Epub 2011 Jun 20. Blood. 2011. PMID: 21690556 Free article. Clinical Trial.
Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT.
de Pagter PJ, Schuurman R, Keukens L, Schutten M, Cornelissen JJ, van Baarle D, Fries E, Sanders EA, Minnema MC, van der Holt BR, Meijer E, Boelens JJ. de Pagter PJ, et al. Among authors: meijer e. Bone Marrow Transplant. 2013 Nov;48(11):1460-4. doi: 10.1038/bmt.2013.78. Epub 2013 Jun 17. Bone Marrow Transplant. 2013. PMID: 23771003
1,036 results